CL2011002972A1 - Compuestos derivados de imidazol sustituido, moduladores de la actividad de receptores x del higado (lxr); composicion farmaceutica, utiles en el tratamiento de trastornos como aterosclerosis, resistencia a la insulina, artrosis, diabetes, enfermedad de alzheimer, entre otras. - Google Patents
Compuestos derivados de imidazol sustituido, moduladores de la actividad de receptores x del higado (lxr); composicion farmaceutica, utiles en el tratamiento de trastornos como aterosclerosis, resistencia a la insulina, artrosis, diabetes, enfermedad de alzheimer, entre otras.Info
- Publication number
- CL2011002972A1 CL2011002972A1 CL2011002972A CL2011002972A CL2011002972A1 CL 2011002972 A1 CL2011002972 A1 CL 2011002972A1 CL 2011002972 A CL2011002972 A CL 2011002972A CL 2011002972 A CL2011002972 A CL 2011002972A CL 2011002972 A1 CL2011002972 A1 CL 2011002972A1
- Authority
- CL
- Chile
- Prior art keywords
- disorders
- lxr
- atherosclerosis
- alzheimer
- modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE DAN A CONOCER COMPUESTOS DERIVADOS DE IMIDAZOL, ISÓTOPOS O SALES FA RMACÉ UTICA MENTE ACEPTABLES, MODULADORES DE LA ACTIVIDAD DE LOS RECEPTORES X DEL HÍGADO (LXR); COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN DICHOS COMPUESTOS, Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES COMO: ATEROSCLEROSIS, RESISTENCIA A LA INSULINA, ARTROSIS, ACCIDENTE CEREBROVASCULAR, HIPERGLUCEMIA, DISLIPIDEMIA, PSORIASIS, FORMACIÓN DE ARRUGAS EN LA PIEL RELACIONADAS CON EXPOSICIÓN A UY Y LA EDAD, DIABETES, CÁNCER, ENFERMEDAD DE ALZHEIMER, INFLAMACIÓN, TRASTORNOS INMUNOLÓGICOS, TRASTORNOS LIPÍDICOS, OBESIDAD, DEGENERACIÓN MACULAR, ESTADOS CARACTERIZADOS POR UNA FUNCIÓN DE BARRERA EPIDÉRMICA ALTERADA, ESTADOS DE PROLIFERACIÓN EN EXCESO O DIFERENCIACIÓN ALTERADA DE LA EPIDERMIS O MEMBRANA MUCOSA O TRASTORNOS CARDIOVASCULARES.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18173609P | 2009-05-28 | 2009-05-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2011002972A1 true CL2011002972A1 (es) | 2012-08-17 |
Family
ID=43223342
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2011002972A CL2011002972A1 (es) | 2009-05-28 | 2011-11-24 | Compuestos derivados de imidazol sustituido, moduladores de la actividad de receptores x del higado (lxr); composicion farmaceutica, utiles en el tratamiento de trastornos como aterosclerosis, resistencia a la insulina, artrosis, diabetes, enfermedad de alzheimer, entre otras. |
Country Status (30)
Country | Link |
---|---|
US (4) | US8618154B2 (es) |
EP (1) | EP2435410B1 (es) |
JP (1) | JP5625050B2 (es) |
KR (1) | KR101676704B1 (es) |
CN (1) | CN102648184B (es) |
AR (1) | AR078049A1 (es) |
AU (1) | AU2010254082B2 (es) |
BR (1) | BRPI1013259B8 (es) |
CA (1) | CA2761934C (es) |
CL (1) | CL2011002972A1 (es) |
CO (1) | CO6470826A2 (es) |
CY (1) | CY1119407T1 (es) |
DK (1) | DK2435410T3 (es) |
EA (1) | EA019960B1 (es) |
ES (1) | ES2620451T3 (es) |
HR (1) | HRP20170194T1 (es) |
IL (1) | IL216176A (es) |
LT (1) | LT2435410T (es) |
MX (1) | MX2011012559A (es) |
MY (1) | MY153958A (es) |
NZ (1) | NZ596330A (es) |
PE (1) | PE20120797A1 (es) |
PL (1) | PL2435410T3 (es) |
PT (1) | PT2435410T (es) |
SG (1) | SG176247A1 (es) |
SI (1) | SI2435410T1 (es) |
TN (1) | TN2011000585A1 (es) |
TW (1) | TWI488844B (es) |
WO (1) | WO2010138598A2 (es) |
ZA (1) | ZA201108181B (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2011012559A (es) * | 2009-05-28 | 2012-06-08 | Exelixis Patent Co Llc | Moduladores de lxr. |
AR088728A1 (es) * | 2011-03-25 | 2014-07-02 | Bristol Myers Squibb Co | Moduladores de lxr como prodroga de imidazol |
EP2820013B9 (en) | 2012-03-02 | 2019-01-09 | Ralexar Therapeutics, Inc. | Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions |
CA3211094A1 (en) * | 2012-08-13 | 2014-02-20 | The Rockefeller University | Treatment and diagnosis of melanoma |
CN105188380B (zh) | 2013-03-15 | 2017-08-15 | 百时美施贵宝公司 | Lxr调节剂 |
JP6442475B2 (ja) * | 2013-03-15 | 2018-12-19 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Lxr調節因子 |
DK3041835T3 (da) | 2013-09-04 | 2020-07-13 | Ellora Therapeutics Inc | Modulatorer af lever-X-receptorer (LXR) |
MX2016002930A (es) | 2013-09-04 | 2016-12-02 | Ralexar Therapeutics Inc | Moduladores del receptor x hepatico (lxr). |
EP3091970B1 (en) | 2014-01-10 | 2020-10-28 | Rgenix, Inc. | Lxr agonists and uses thereof |
KR101815734B1 (ko) | 2015-05-29 | 2018-01-05 | 가톨릭대학교 산학협력단 | miR-7, miR-18a 또는 miR-18b를 유효성분으로 포함하는 대사성 질환의 예방 또는 치료용 약학적 조성물 |
EP3402477A4 (en) | 2016-01-11 | 2019-08-21 | The Rockefeller University | METHODS FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH SUPPRESSIVE CELLS DERIVED FROM MYELOID CELLS |
US11214536B2 (en) | 2017-11-21 | 2022-01-04 | Inspirna, Inc. | Polymorphs and uses thereof |
CN114126618A (zh) | 2019-07-15 | 2022-03-01 | 诺华股份有限公司 | 用肝脏x受体激动剂治疗睑板腺功能障碍的方法 |
CN110305141B (zh) * | 2019-07-18 | 2022-01-11 | 深圳市三启药物开发有限公司 | 一种螺(3,3’-异丙基吡咯烷氧化吲哚)类肝x受体调节剂及其制备方法和应用 |
CN114728875A (zh) | 2019-12-13 | 2022-07-08 | 因思博纳公司 | 金属盐及其用途 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
US4444784A (en) | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
DK149080C (da) | 1980-06-06 | 1986-07-28 | Sankyo Co | Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre |
US5354772A (en) | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
WO1984002131A1 (en) | 1982-11-22 | 1984-06-07 | Sandoz Ag | Analogs of mevalolactone and derivatives thereof, processes for their production, pharmaceutical compositions containing them and their use as pharmaceuticals |
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
US5177080A (en) | 1990-12-14 | 1993-01-05 | Bayer Aktiengesellschaft | Substituted pyridyl-dihydroxy-heptenoic acid and its salts |
DE69232537T2 (de) | 1991-09-17 | 2002-10-24 | Salk Inst For Biolog Studies L | Rezeptoren der steroid/thyroid superfamilie von rezeptoren |
EP1019059A4 (en) | 1997-01-24 | 2004-01-14 | Univ California | USE OF FXR, PPAR-ALPHA AND LXR-ALPHA ACTIVATORS TO RESTORE THE BARRIER FUNCTION, TO PROMOTE EPIDERMIS DIFFERENTIATION, AND TO PROLIFERATE |
EP1115853A2 (en) | 1998-09-23 | 2001-07-18 | Ludmila Solomin | Analysis of ligand activated nuclear receptors in vivo |
EP1140079B1 (en) | 1998-12-23 | 2009-06-03 | Glaxo Group Limited | Assays for ligands for nuclear receptors |
ATE330632T1 (de) | 1999-03-26 | 2006-07-15 | Hope City | Selektion von fxr-rezeptormodulatoren |
IL147022A0 (en) | 1999-06-18 | 2002-08-14 | Cv Therapeutics Inc | Compositions and methods for increasing cholesterol efflux and raising hdl using atp binding cassette transporter protein abc1 |
AU2001262984A1 (en) | 2000-05-03 | 2001-11-12 | Tularik, Inc. | Treatment of hypertriglyceridemia and other conditions using lxr modulators |
US6924311B2 (en) | 2001-10-17 | 2005-08-02 | X-Ceptor Therapeutics, Inc. | Methods for affecting various diseases utilizing LXR compounds |
US7482366B2 (en) * | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
WO2004011446A1 (en) * | 2002-07-26 | 2004-02-05 | Bayer Pharmaceuticals Corporation | Indane, dihydrobenzofuran, and tetrahydronaphthalene carboxylic acid derivatives and their use as antidiabetics |
US7109227B2 (en) * | 2002-08-26 | 2006-09-19 | National Health Research Institutes | Imidazolamino compounds |
WO2004106307A2 (fr) * | 2003-05-27 | 2004-12-09 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Nouveaux derives d’imidazoles, leur preparation et leur utilisation en tant que medicament |
WO2005047266A1 (en) * | 2003-11-14 | 2005-05-26 | Lorus Therapeutics Inc. | Aryl imidazoles and their use as anti-cancer agents |
BRPI0507632A (pt) * | 2004-02-11 | 2007-07-03 | Irm Llc | compostos e composições como moduladores de lxr |
SG162803A1 (en) * | 2005-06-27 | 2010-07-29 | Exelixis Inc | Imidazole based lxr modulators |
JP5237799B2 (ja) * | 2005-06-27 | 2013-07-17 | エグゼリクシス パテント カンパニー エルエルシー | ピラゾールベースのlxrモジュレーター |
JP5399262B2 (ja) * | 2006-12-08 | 2014-01-29 | エグゼリクシス パテント カンパニー エルエルシー | Lxrおよびfxrのモジュレーター |
MX2011012559A (es) * | 2009-05-28 | 2012-06-08 | Exelixis Patent Co Llc | Moduladores de lxr. |
-
2010
- 2010-05-26 MX MX2011012559A patent/MX2011012559A/es active IP Right Grant
- 2010-05-26 PT PT107219024T patent/PT2435410T/pt unknown
- 2010-05-26 US US13/319,937 patent/US8618154B2/en active Active
- 2010-05-26 AU AU2010254082A patent/AU2010254082B2/en active Active
- 2010-05-26 CN CN201080033601.2A patent/CN102648184B/zh active Active
- 2010-05-26 LT LTEP10721902.4T patent/LT2435410T/lt unknown
- 2010-05-26 JP JP2012513215A patent/JP5625050B2/ja active Active
- 2010-05-26 SG SG2011087459A patent/SG176247A1/en unknown
- 2010-05-26 PE PE2011002005A patent/PE20120797A1/es active IP Right Grant
- 2010-05-26 PL PL10721902T patent/PL2435410T3/pl unknown
- 2010-05-26 NZ NZ596330A patent/NZ596330A/xx unknown
- 2010-05-26 KR KR1020117031397A patent/KR101676704B1/ko active IP Right Grant
- 2010-05-26 WO PCT/US2010/036211 patent/WO2010138598A2/en active Application Filing
- 2010-05-26 CA CA2761934A patent/CA2761934C/en active Active
- 2010-05-26 SI SI201031427A patent/SI2435410T1/sl unknown
- 2010-05-26 DK DK10721902.4T patent/DK2435410T3/da active
- 2010-05-26 EA EA201171488A patent/EA019960B1/ru not_active IP Right Cessation
- 2010-05-26 ES ES10721902.4T patent/ES2620451T3/es active Active
- 2010-05-26 BR BRPI1013259A patent/BRPI1013259B8/pt active IP Right Grant
- 2010-05-26 MY MYPI2011006278A patent/MY153958A/en unknown
- 2010-05-26 EP EP10721902.4A patent/EP2435410B1/en active Active
- 2010-05-28 TW TW099117252A patent/TWI488844B/zh active
- 2010-05-28 AR ARP100101870A patent/AR078049A1/es not_active Application Discontinuation
-
2011
- 2011-11-07 IL IL216176A patent/IL216176A/en active IP Right Grant
- 2011-11-08 ZA ZA2011/08181A patent/ZA201108181B/en unknown
- 2011-11-16 TN TNP2011000585A patent/TN2011000585A1/en unknown
- 2011-11-24 CL CL2011002972A patent/CL2011002972A1/es unknown
- 2011-11-25 CO CO11161736A patent/CO6470826A2/es active IP Right Grant
-
2013
- 2013-11-21 US US14/085,926 patent/US20140163081A1/en not_active Abandoned
-
2015
- 2015-05-04 US US14/703,247 patent/US20150299136A1/en not_active Abandoned
-
2016
- 2016-06-07 US US15/175,425 patent/US20160280661A1/en not_active Abandoned
-
2017
- 2017-02-06 HR HRP20170194TT patent/HRP20170194T1/hr unknown
- 2017-04-05 CY CY20171100403T patent/CY1119407T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2011002972A1 (es) | Compuestos derivados de imidazol sustituido, moduladores de la actividad de receptores x del higado (lxr); composicion farmaceutica, utiles en el tratamiento de trastornos como aterosclerosis, resistencia a la insulina, artrosis, diabetes, enfermedad de alzheimer, entre otras. | |
CO6480918A2 (es) | Antagonistas policíclicos de receptores de ácido lisofosfatídico. | |
BR112012020558A2 (pt) | moduladores do receptor de androgênio e seus usos | |
CO6771417A2 (es) | Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis | |
CO2017003070A2 (es) | Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos | |
BR112012013431A8 (pt) | composto, composição farmacêutica e seu uso | |
CR11854A (es) | Compuestos de piridina | |
CL2011002430A1 (es) | Variante de peptido natriuretico de tipo c (cnp); composicion farmaceutica que la comprende; metodo de produccion, celula huesped y uso de dicha variante. | |
CL2012000620A1 (es) | Formulaciones farmaceuticas de un anticuerpo anti cd-20; uso de la formulacion para tratar enfermedad o trastorno que pueda corregirse mediante tratamiento con anticuerpo anti-cd20. | |
CO6680708A2 (es) | Compuesto modulares de estrógenos y composiciones que comprenden los mismos | |
AR091000A1 (es) | Polipeptidos de union a receptores de quimiocinas | |
CR20110466A (es) | Anticuerpos biespecíficos anti-erbb-3/anti-c-met | |
CL2008002787A1 (es) | Compuestos derivados de piperidina, que presentan actividad moduladora sobre la actividad del receptor gpr 119; composición farmacéutica que comprende a dichos compuestos; y su uso en el tratamiento de enfermedades tales como diabetes tipo 1 y 2, hiperllpidemia, enfermedad coronaria, obesidad y disfuncion erectil. | |
BR112014026952A2 (pt) | derivados de aminopirimidina pirazol como moduladores lrrk2 | |
ES2657686T3 (es) | Composición para aplicaciones cosméticas, farmacéuticas o dietéticas | |
BR112015015468B8 (pt) | Composto, e, composição farmacêutica | |
EA201100691A1 (ru) | Антагонисты рецепторов лизофосфатидной кислоты | |
ECSP055699A (es) | Indazoles, benzotiazoles y benzoisotiazoles, y su preparacion y usos | |
EP4332576A3 (en) | Synergistic enhancement of the delivery of nucleic acids via blended formulations | |
EA201270467A1 (ru) | Полициклические соединения в качестве антагонистов рецепторов лизофосфатидной кислоты | |
BR112015012555A2 (pt) | derivados de benzimidazol como antagonistas de ep4 | |
AR083784A1 (es) | Polipeptidos de enlace de los receptores de quimiocina | |
ECSP11011139A (es) | Anticuerpos contra la angiopoyetina 2 humana | |
HN2012000889A (es) | Derivados de la cromenona con actividad anti-tumoral | |
ECSP066734A (es) | Derivados de ácido 7-fenilamino-4-quinolona-3-carboxílico, métodos para su producción y su uso como medicamentos |